MBX Biosciences Inc

Research MBX Biosciences Inc (MBX) on Bullrun: market cap USD 2.56B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMBX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.56B
• Financial periodFY2025
• Net income-USD 87.00M
• Free cash flow-USD 81.88M

Valuation Snapshot

latest market cap is USD 2.56B.

About MBX Biosciences Inc

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Frequently asked questions

What is MBX Biosciences Inc's market cap?

MBX Biosciences Inc's market capitalization is USD 2.56B.

What does MBX Biosciences Inc do?

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.